Inventiva S.A Total Liabilities
Inventiva S.A total liabilities. Based on the latest financial reports, Inventiva S.A (IVA) has total liabilities worth €278.03 Million EUR (≈ $325.05 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IVA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Inventiva S.A (2013–2025)
Total liabilities of Inventiva S.A from 2013 to 2025. This chart illustrates how Inventiva S.A's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Inventiva S.A to see how much of total assets are deployed in long-term investments.
Inventiva S.A Competitors by Total Liabilities
The table below lists competitors of Inventiva S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canadian General Investments Ltd
TO:CGI
|
Canada | CA$202.32 Million |
|
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
|
China | CN¥10.75 Billion |
|
Tejas Networks Limited
NSE:TEJASNET
|
India | Rs65.60 Billion |
|
Focused Photonics Hangzhou Inc
SHE:300203
|
China | CN¥5.87 Billion |
|
Zhejiang Zhaofeng Mechanical and Electronic Co Ltd
SHE:300695
|
China | CN¥429.77 Million |
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
China | CN¥2.46 Billion |
|
Railtel Corporation Of India Limited
NSE:RAILTEL
|
India | Rs35.68 Billion |
|
Orient International Enterprise Ltd
SHG:600278
|
China | CN¥11.22 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Inventiva S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Inventiva S.A asset portfolio.
Liquidity & Leverage Metrics
Inventiva S.A Total Liabilities Ratios Explained
Inventiva S.A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inventiva S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inventiva S.A (2013–2025)
The table below shows the annual total liabilities of Inventiva S.A from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €278.03 Million ≈ $325.05 Million |
+23.23% |
| 2024-12-31 | €225.61 Million ≈ $263.77 Million |
+122.08% |
| 2023-12-31 | €101.59 Million ≈ $118.77 Million |
+44.04% |
| 2022-12-31 | €70.53 Million ≈ $82.45 Million |
+112.96% |
| 2021-12-31 | €33.12 Million ≈ $38.72 Million |
+19.53% |
| 2020-12-31 | €27.71 Million ≈ $32.39 Million |
+77.98% |
| 2019-12-31 | €15.57 Million ≈ $18.20 Million |
-14.54% |
| 2018-12-31 | €18.22 Million ≈ $21.30 Million |
+75.86% |
| 2017-12-31 | €10.36 Million ≈ $12.11 Million |
-21.15% |
| 2016-12-31 | €13.14 Million ≈ $15.36 Million |
-26.22% |
| 2015-12-31 | €17.81 Million ≈ $20.82 Million |
-17.67% |
| 2014-12-31 | €21.63 Million ≈ $25.28 Million |
-23.05% |
| 2013-12-31 | €28.11 Million ≈ $32.86 Million |
-- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more